Approach social media with caution? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Approach social media with caution?


Pharmaceutical Technology Europe
Volume 22, Issue 9


Fedra Pavlou
No one can deny the power of social media; it has revolutionised communication and empowered consumers, creating a medium that allows the free flow of information with no authority to control it.

Though slow on the uptake, pharma companies are well aware that they must find ways to utilise social media tools to engage with their customers and patients; they can't afford not to. However, this absence of regulatory control poses a significant problem; companies must be cautious. The industry is well aware that messages relating to brand name drugs should clearly disclose product benefits and risks, but with the limitations of Twitter and Facebook, for example, the provision of such information is impossible. So companies have been looking to alternative and more innovative methods to communicate.

Many have jumped on the patient communities bandwagon, developing forums that allow patients to learn and to communicate with each other. This kind of platform is powerful; not only does it provide a valuable service for patients, but it also gives companies invaluable information about patient experiences with its own as well as with competitor therapies. Meanwhile, the industry has also been taking advantage of the intelligence-rich physician communities, such as US-based Sermo and Mescape Physician Connect. While these services are free to physicians, the service providers sell access to data on doctors' conversations to pharma companies, according to a recent report by Ernst & Young (Progressions Pharm 3.0). Though this strategy carries some ethical question marks, it is an ingenious business idea and worth every penny to the industry. The financial services industry is also cashing in. For example, Bloomberg partnered with Sermo to allow its subscribers access to physician comments enabling them to understand and predict trends in the industry that would impact pharma company share prices!

While pharma companies are still dabbling with social media, there is no doubt that it will play a key role in companies' service provision moving forward. The industry must no longer view social media tools as a fad or an inconvenience, but it must look to incorporate social media communication into its overall brand management strategy. Caution must of course be applied; no company wants to be slapped on the wrist for inappropriate use of social media tools (Pharma struggling with social media). However, the pharmaceutical companies that use them intelligently will be certain to reap the rewards.

Fedra Pavlou
Editor-in-Chief

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology Europe,
Click here